Verona Pharma, the UK-based biopharmaceutical company focused on respiratory diseases, has appointed David Moskowitz to the new position of vice president of capital markets strategy & investor relations.
Most recently, Moskowitz offered IR advice to healthcare companies through his own consultancy Passage Creek. Prior to that, he worked as vice president of strategy and corporate communications at Biocept and vice president of IR at Trovagene.
Before moving into IR, Moskowitz was a seasoned equity research analyst who worked at a range of sell-side firms. Among those roles, he served as head of healthcare research at FBR Capital Markets and director of equity research at Caris & Co.
In 2011 he was named best stock picker among US biotech analysts by the StarMine Analyst Awards, according to a statement by Verona Pharma.
‘We are delighted to welcome David to Verona Pharma,’ says Jan-Anders Karlsson, Verona Pharma’s CEO, in the company statement. ‘His experience and insights make him ideally suited to support our investor relations program and goals.
‘He will play an instrumental role in forming and implementing our IR strategy as we plan to start phase three trials with first-in-class product candidate Ensifentrine in 2020.’
Verona Pharma is listed in the US on the Nasdaq Global Market and in the UK on the London Stock Exchange.
